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Mitochondrial DNA mutations and polymorphisms have been the focus of intensive investigations for well over a decade
in an attempt to understand how they aﬀect fundamental processes such as cancer and aging. Initial interest in mutations
occurring in mitochondrial DNA of cancer cells diminished when most were found to be the same mutations which occurred
during the evolution of human mitochondrial haplogroups. However, increasingly correlations are being found between various
mitochondrial haplogroups and susceptibility to cancer or diseases in some cases and successful aging in others.
1.Introduction
Mitochondria play essential and diverse roles in the phys-
iology of eukaryotic cells. These structures are not only
indispensable for ATP production and participate in numer-
ous intermediate metabolic reactions but also play a central
role in calcium homeostasis, apoptosis, cell signaling, and
diﬀerentiation. Impairment of mitochondrial functions has
been implicated in a wide variety of human pathologies
including cancer and age-related diseases such as type II
diabetes mellitus (DM II), Alzheimer’s disease, degenerative
arthritis, ischemic heart disease, and age-related macular
degeneration [1–4].
Until recently aerobic glycolysis of cancer cells received
little attention in oncology despite being one of the ﬁrst
observations made in the ﬁeld [5]. Recent progress in the
understanding of cancer molecular genetics, biochemistry,
and proteomics has renewed interest in “mitochondrial
oncology” [2, 4]. It is now widely understood that, unlike
most normal cells, cancer cells are dependent on glycolysis
for energy production and that an energetic switch is an
indispensible step in malignant transformation [6], since
aerobic glycolysis confers a growth advantage to tumor
cells [7] and disrupted OXPHOS provides a proliferative
advantage [8]. New attempts to analyze the signiﬁcance
of mitochondria in oncology encompass the increasingly
important debate whether mtDNA mutations or poly-
morphisms are actually the cause or an eﬀect of tumor
progression. A growing number of reports support the
hypothesis that mitochondrial functions are profoundly
alteredintransformedcellsandthatmtDNApolymorphisms
are important for the processes of cell transformation [3, 4,
9, 10].
Somatic mtDNA mutations are a general phenomenon
occurring during cell transformation and ageing. In the last
tenyearsmtDNAmutationshavebeenfound insolid tumors
including carcinomas and sarcomas, and also leukemias and
lymphomas [1, 3, 11–13] .A tt h es a m et i m er e p o r t so fp r e -
mature aging in mutant mice with greatly increased rates of
mitochondrial DNAmutagenesis—so-called “mitochondrial
mutator mice”—conﬁrmed that accumulation of mtDNA
mutations is a key mechanism of aging [14]. Comprehensive
scanning of mtDNA in cancer cells detected functionally
relevant point mutations [15–17], but also speciﬁc mtDNA
polymorphisms in polypeptide-encoding genes and the D-
loop were found in as many as 50% of cancer patients2 Journal of Aging Research
[18–20]. MtDNA mutations and polymorphisms can cause
alterations in the encoded proteins [21, 22] and in con-
sequence may compromise the respiratory chain function
and stimulate abundant ROS production [15, 23]. Proteins
with altered sequences as the result of somatic mtDNA
mutations have been shown to have disturbed assembly and
stabilityandthereforedefectivestructureofrespiratory chain
complexes leading to OXPHOS deﬁciency [21, 22, 24, 25].
Such mutations could also aﬀect cells during aging.
An analogous correlation has been proposed for cells
with speciﬁc rare mtDNA polymorphisms [26–30]. Thus,
the diﬀerent mtDNA sequences reported in a variety of
human cancer cells are thought to contribute to oxidative
respiratory malfunction. In particular a few reports conﬁrm
that mtDNA genome sequence heterogeneity is the cause
of subsequent mitochondrial function alterations includ-
ing OXPHOS deﬁciency, ROS overproduction, and ﬁnally
upregulation of signaling pathways associated with cell
maturation, proliferation, and cell death[12, 25, 31, 32]. The
codependence of cancer growth rate, metastatic potential
and mtDNA mutations has recently been established in a
mouse model [15]. Moreover, the apparent conundrum of
whether mtDNA mutations found in tumors are a cause or
a consequence of the carcinogenic process has recently also
beenpartially solvedafter thedemonstrationthatpathogenic
mtDNA mutations lead to excessive reactive oxygen species
signaling [33, 34], diminish cellular apoptotic potential
[35], initiate mitochondria-nucleus signaling that promotes
a cellular invasive phenotype [36–38], regulate epigenetic
modiﬁcations in the nucleus [10], and aﬀect nucleotide
pools and chromosomal stability [39]. Although numerous
mtDNA polymorphisms and mutations have been identi-
ﬁed in various tumors, the pathogenic implications (cell
growth or transformation promotion? metastatic potential
promotion?) of many of these mtDNA variants remain
unclearand need critical evaluationin orderto avoidpitfalls,
misinterpretations, and erroneous conclusions [40, 41].
Comprehensive analysis by Bandelt et al. [41–43]s h o w s
that oncology, forensic science, population genetics, and
clinicalliteratureonmtDNAis often compromisedby unsat-
isfactory results in many studies, including ﬂawed sequence
data, artiﬁcial recombinant sequences or interpretative
shortcomings [43–45].In particularphantommutationsand
phantom mutation hotspots lead to misidentiﬁcation of
pathologic somatic mutations and to misinterpretations in
all kinds of aspects of clinical mtDNA studies [46, 47]. Many
listed mutations when reanalyzed were found to actually be
polymorphisms, including polymorphisms known to deﬁne
major haplogroups. It should be stressed that those artifacts
have been inadvertently regarded as novel and pathogenic.
Bandelt et al. proposed a paradigm of evaluation ofsequence
quality and detection of potential problems when inferring
the pathogenic status of an mtDNA mutation to avoid false
positive results [48]. Some authors have also called for
stringent quality control of mtDNA data by haplogroup-
directed database comparisons [47, 49]. Therefore, in this
paper we mainly focus on mtDNA polymorphisms and
mitochondrial haplogroups and their role in cancer and
aging.
2.Mitochondrial DNA Polymorphisms
inCancer
The use of mitochondrial DNA polymorphisms as bio-
markers is rapidly expanding in metabolic disease diagnos-
tics, the analysis of human migration patterns, and human
identiﬁcation in forensic sciences [2, 11, 12]. Although
somatic mtDNA mutations have been reported in many
types of cancer, very few reports have documented the
prevalence of inherited mitochondrial DNA polymorphisms
in cancer patients and its comparison to healthy control
populations.
The ﬁrst interesting and widely investigated mtDNA
polymorphism in the cancer ﬁeld was A10398G, ﬁrst
described as causative factor in breast cancer development
[50–52]. In particular we have shown the abundance of
the 10398G polymorphism in a Polish breast cancer cohort.
23% of patients with biopsy-proven breast cancer carried
the 10398G variant, while in the healthy group only 3%
(P = .0008). This polymorphism is of great interest as
10398 locus in mtDNA is highly polymorphic. While the
revised Cambridge reference sequence [53] lists the wild
type base as A, the alternative base (G) is also prevalent
in many populations [54]. Amongst 2704 complete coding
region sequences reported in the mtDB database, the base
is A in 54% (1461), G in 46% (1242), and T in 1 case
[54, 55]. Moreover, analyses of this polymorphism in the
clinical context yielded contradictory ﬁndings. The 10398A
appears to increase the risk of Parkinson’s disease [56],
Alzheimer’s disease [57], and amyotrophic lateral sclerosis
[58], but in contrast it protects against cardiomyopathy
in patients with Friedreich’s ataxia [59]. At the same time
Canter et al. found an increased frequency of the 10398A
in African-American women with invasive breast cancer
[60]. In contrast, in another study, the 10398A frequency
was not increased in an African American breast cancer
cohort when compared with controls [50]. The signiﬁcant
diﬀerence reported by us between 10398G distribution in
breast cancer patients and breast cancer-free women with
negative family history seems to prove the unique role of the
A10398G polymorphism in breast cancer predisposition. We
believe that A10398G might be considered as a contributing
factor in carcinogenesis and as variant modifying the risk of
developing breast cancer [19, 61]. In contrast, inheritance
of 10398A has been postulated to increase incidence and
severity of prostate cancer in African-American men as
compared with other ethnic groups [52]. Concerning the
pathophysiological role of A10398G it must be underlined
that the amino acid with 10398A is threonine, and with
10398G alanine. Amongst 61 analyzed species (including
humans), theamino acidatposition114isthreoninein44%,
and alanine in 30% and a diﬀerent amino acid in 26% [62].
The substitution of threonine—a polar, neutral amino acid
with hydropathy index −0.7foralanine—a nonpolar, neutral
amino acid with hydropathy index of 1.8 [63]—is signiﬁcant
and relatively nonconservative as reﬂected by the Grantham
value of 58 [64]. The methyl group of alanine is nonreactive
and isthusalmost neverdirectly involvedin proteinfunction
and bonding [65, 66].Journal of Aging Research 3
Concerning other mtDNA loci, multiple interesting
mtDNApolymorphisms havebeenreported in prostate[67],
thyroid [68], and oral cancer cases [69] with breast cancer
as the most widely explored research topic [20, 27, 70–
74]. It was shown that breast cancer patients with multiple
mtDNA D-loop (CA)(n) polymorphisms have signiﬁcantly
poorer disease-free survival than those with one copy of
the mtDNA D-loop (CA)(n) polymorphism [70]. mtDNA
variation, particularly in the D310 segment, was indicated
to be a causative factor of breast cancer development.
In particular the C16189T polymorphism seems to be of
potential pathophysiological impact as it has been associated
with susceptibility to dilated cardiomyopathy (DCM) [75],
insulin resistance, and development of DM II in adult
life and vascular pathologies including lacunar cerebral
infarction and cardiovascular diseases [76]. In a breast
cancer cohort study we detected a signiﬁcantly greater
incidence of mtDNA polymorphisms T239C, A263G, and
C16207T and a signiﬁcant lower incidence of A73G, C150T,
T16183C, T16189C, C16223T, and T16362C compared to
controls [27]. In breast cancercohort NADH-dehydrogenase
mtDNA encoded genes were also rich in polymorphisms,
in particular very rare polymorphisms such as A4727G,
G9947A, A10044G, A10283G, T11233C, and C11503T [19].
A tt h es a m et i m ew eh a v ea l s or e p o r t e dm u l t i p l e
mtDNA polymorphisms in vulvar cancer cases, in particular
19 speciﬁc uncommon polymorphisms and one polymor-
phism not reported previously (C498delC). In vulvar cancer
cases overrepresented polymorphisms included C16192T,
C16256T and C16270T, what is interesting is that, all are
speciﬁc for haplogroup U, whereas the 16223T polymor-
phism characteristic for haplogroups I, W, and X was
underrepresented [28, 54]. In all the studies, including
breast cancer, endometrial adenocarcinoma, and vulvar
carcinoma, polymorphisms were predominantly found in
mtDNAhypervariableregionsHV1(16024–16383)andHV2
(57–333) [26–28].
In the case of hepatocellular carcinoma (HCC), polymor-
phisms including 16266T, 16293G, 16299G, 16303A, 242T,
368G, and 462T were associated with increased risk for
alcohol-dependent HCC. At the same time the 523A/del was
associated with increased risks of both alcohol-dependent,
and independent HCC. Moreover, 489T/152T, 489T/523A,
and 489T/525C haplotypes were signiﬁcantly reduced in
HBV-positive HCC patients in comparison to HBV-negative
patients. Haplotypes 489C and 152T, 249A, 309C, 523Del,
or 525Del were associated signiﬁcantly with an increase of
alcohol-HCC risk [77].
6221C and 7389C polymorphisms were signiﬁcantly
associated with prostate cancer (P<. 05) and in strong
linkage disequilibrium with each other (r(2) > 0.6) in
African-American men [78], while no speciﬁc mtDNA
polymorphisms appeared to have a signiﬁcant eﬀect on a
predisposition to prostate cancer in the Korean population
[79].
In summary we and others have hypothesized that
patients bearing some of the common mitochondrial poly-
morphisms are at higher risk of cancer development,
with a particularly interesting role of haplogroup-speciﬁc
mtDNA polymorphisms. Moreover, it might be tempt-
ing to suggest that in cancer patients a similar situation
i sf o u n da st h a tr e p o r t e db yL e h t o n e ne ta l .[ 80]f o r
patients with sensorineural hearing impairment—that is, in
both cases, aﬀected persons have more rare substitutions
in their mitochondrial DNA than the healthy control
population. Similar results have been obtained for other
diseases related to mitochondria [81]. It is diﬃcult to
explain this at present, but possibly these rare mutations
have an eﬀect on mitochondrial function making persons
in whom they are present more susceptible to certain
diseases.
3.Mitochondrial Mutationsand
Polymorphisms inAging
Numerous papers have analyzed the increased occurrence
of mitochondrial mutations and deletions in aging cells
in various organisms [82–84]. The fact that older cells in
various tissues, especially in postmitotic ones, accumulate
both point mutations and deletions in mitochondrial DNA
is undisputed, but there have been a number of problems
interpreting these results. First, relatively high percentages of
mutations are known to be required to aﬀect the respiratory
chain, on the basis of data from patients with mitochondrial
diseases. Second, the correlation of point mutations and
deletions with aging is not proof of causality—only of
coexistence. Another problem which has been controversial
is what the eﬀects of the mutations are—do they cause a
vicious cycle of ROS release, as was postulated by Harman
[85], with more and more new mutations leading inevitably
to cell death?
In the last years two models have resolved some, but
not all of the problems which have been raised in studies of
aging and mitochondria. The ﬁrst was mentioned above—
the mutator mouse, obtained independently by two groups
[86, 87] with a mutated mitochondrial DNA polymerase
which led to accumulation of large numbers of mutations
in the mitochondrial DNA. The mice showed symptoms
of premature aging—and, as the mutations came before
the aging this was proof of causality. There are still, how-
ever, some problems with the interpretation of the results
obtained with these models. Why are heterozygous mice
which accumulate a high number of mutations healthy?
Are deleted mtDNA molecules the cause of aging? Do they
occur? The diﬀerent techniques used and diﬀerent results
obtained by the two groups make it diﬃcult to analyze what
exactly is happening during the aging process, but some
things do appear to be clear—there are numerous point
mutations, they lead to cell death and eventually aging, and
all this takes place without any excessive production of ROS
[88–90].
The secondresultwas perhaps less spectacular than those
obtained with the mutator mouse but is very important
for solving the problem of whether and how low levels of
mitochondrial DNA mutations can aﬀect the functioning
of cells. Dufour et al. [91] found that a mitochondrial
respiratory chain deﬁciency in neurons which was caused
by a nuclear mutations when present in only 20% of4 Journal of Aging Research
the mitochondria caused degeneration of adjacent neurons.
This points to a solution of the problem that the levels of
mutations found in aging tissues are too low.
Thus, mitochondrial mutations are now generally
believedtobe involvedin the agingprocess. The involvement
of ROS will be discussed in a separate section as will
the eﬀects of mitochondrial polymorphisms—through their
grouping in haplogroups.
4.Mitochondrial Haplogroupsin
CancerandAging
Human mtDNA is highly polymorphic. On the basis of
certain SNPs present in mtDNA, the human population can
be divided into haplogroups. Analysis of their distribution
among the population enables reconstruction of ancient
human migrations. Mutations creating certain haplogroups
(that became polymorphisms over time) were suggested to
aﬀect coupling eﬃciency of the electron transport chain,
enabling adaptation to life in diﬀerent climatic condi-
tions [2]. It is estimated that around 25% of mtDNA
polypeptide sequence variation, 10–20% of tRNA variation,
and at least some of rRNA variation contributes to this
eﬀect.
MtDNA haplogroup variation seems to confer genetic
susceptibility for several conditions, as indicated by numer-
ousstudies.Mitochondrialgeneticbackgroundwasshown to
aﬀect the risk of visual failure caused by Leber’s Hereditary
Optic Neuropathy (LHON), as mutation occurrence in
patients with haplogroup J or K correlated with an elevated
risk of developing the condition, whereas haplogroup H
had a protective eﬀect [2, 11, 92, 93]. A similar eﬀect was
reported for haplogroups M8a and M7b that diminished
and enhanced, respectively, clinical manifestation of LHON
symptoms in a Chinese population [94]. Haplogroup H1
was shown to have protective eﬀects on ischemic stroke
risk among Portuguese patients [95]. Parkinson’s disease
(PD) was less frequent among K haplogroup individuals
in the Italian population [96], whereas a study on Polish
PD patients reported a protective eﬀect of haplogroup J in
males [97]. JTWIX supercluster background was associated
with a higher number of nonsynonymous mutations in
complex I genes and an increased risk of PD. At the same
time haplogroups U and K seem to neutralize the harmful
eﬀect of the APOE4 variant in Alzheimer’s disease [98]
and be connected with psychiatric disorders [99]. Moreover,
polymorphisms characteristic for haplogroup J and M were
shown to be associated with longevity in European and
Japanese populations, respectively [100]. On the other hand,
haplogroup J was reported to confer susceptibility to type II
diabetes [101].
In the cancer ﬁeld, signiﬁcant increased risk for breast
cancer development was reported for haplogroup K [102].
Our analysis revealed that mitochondrial haplogroup dis-
tribution in patients with breast cancer greatly diﬀers from
cancer-free controls and the general Polish population.
HaplogroupI wasoverrepresentedinindividualswith cancer
(14% versus 3%; P = .017) in comparison to the general
Polish population, and if the breast cancer cohort was
compared to cancer-free centenarians, haplogroup H was
underrepresented (38% versus 58%; P = .019) [27]. It was
shown that haplogroup M individuals have an increased
risk of breast cancer compared with haplogroup N in
China [103]. In a speciﬁc Chinese population, patients with
mtDNA haplogroup M exhibited an increased risk of breast
cancer development (P = .040) and that this haplogroup-
risk eﬀect was even more pronounced in a subhaplogroup of
M, subhaplogroup D5 (P = .030) [104].
Concerning other types of cancer not as much research
was done as in the case of breast cancer; nevertheless, it was
proven that haplogroup D4a is associated with an increased
risk of thyroid cancer development (P = .028) [104]. The
inheritance of mitochondrial haplogroup U was shown to
be associated with an approximately 2-fold increased risk of
prostate cancer and 2.5-fold increased risk of renal cancer
in white North American individuals and it was indicated
that individuals with this mitochondrial haplotype are in
a high-risk group. Because mitochondrial haplogroup U is
found in 9.35% of the white United States population, more
than 20 million individuals were shown to be in a high
risk group [105]. On the other hand, in a Middle European
population mitochondrial haplogroup frequencies did not
diﬀer signiﬁcantly between patients with prostate cancer
and control population, implying no impact of inherited
mitochondrial DNAvariation onpredisposition toPC[106].
Esophageal cancer (EC) predisposition was investigated in
Taihang Mountain and Chaoshan areas in China. In this
study D5 haplogroup was associated with EC at the general
populationlevelintheTaihang Mountainareaandinwomen
below 60 years of age in the Chaoshan area. It was also
shown that D4a and D5 haplogroups might be risk markers
ofECdevelopment,inparticularD4aand D5fortheTaihang
Mountain area and D and D5 for the Chaoshan area [107].
Mitochondrial haplogroups were also in the focus of
gynecological oncology. In vulvar cancer patients, we again
found signiﬁcant diﬀerences with underrepresentation of
haplogroup H in the cancer cohort. Moreover, in the
comparison with the general Polish population a trend
towards haplogroup U and K overrepresentation was also
noticed (44 versus 19%, P = .009) [28]. The under-
representation of haplogroup H (P = .023) in vulvar
cancer patients was particularly interesting. Haplogroup
H is marked by the T7028C polymorphism. Therefore, if
haplogroup H is underrepresented, 7028T polymorphism
is overrepresented. For vulvar cancer the C7028T RFLP
test has Odds Ratio (OR) and Diagnostic Odds Ratio =
3.11 and indicates Relative Risk (RR) = 2.43 in comparison
to the control (cancer-free centenarians) [28]. A similar
trend was reported for endometrial adenocarcinoma cases.
Analysis revealedthattheendometrialcarcinomapopulation
haplogroup distribution diﬀers from the Polish population
with haplogroup H being strongly underrepresented (P =
.003). In this group patients with endometrial adenocarci-
noma had the T7028C 12% of the time while the general
Polish population carried the T7028C polymorphism 42%
of the time. As a result one had a 5.53 higher chance to
be T7028C carrier and not develop cancer with speciﬁcity
of prediction as high as 0.775 (0.755–0.815) [26]. In bothJournal of Aging Research 5
vulvar and endometrial cancer cases Diagnostic Odds Ratio
of C7028T test was in the range of 3–6, and therefore may
provide a strong clue in investigations of etiology [108]. In
another study patients with endometrial cancers clustered
in haplogroup D with a signiﬁcantly higher frequency
[109].
In summary we believe that, because the patterns of
germline polymorphisms in cancer patients and controls
are diﬀerent, it is possible that the inheritance of speciﬁc
mitochondrial genotypes predisposes individuals to cancer
[110, 111]. Moreover, the co-occurrence of multiple inher-
ited mtDNA SNPs may inﬂuence the disease phenotype
as shown in the case of 12308G and 10398G in breast
cancer [61] or G10680A and T14484C in LHON [112]. One
polymorphism may have a modifying role for increasing
the penetrance and expressivity of other mtDNA genome
variants. In particular, the mitochondrial haplotypes may
play a synergistic role in the development of cancer as is
the case of vision loss in the families carrying the LHON-
associated primary mtDNA mutations. In LHON patients
themitochondrialhaplotypehasbeenshowntoinﬂuencethe
clinical expression [94].
The relationship between mitochondrial haplogroups
and aging in humans is based on analysis of centenarians
in various populations and appropriate control groups;
in some populations certain haplogroups were found to
be overrepresented in relation to controls [113]. A very
attractive hypothesis has been proposed by Wallace [2]t h a t
successful aging is due to uncoupling of the electron chain.
In brief, persons with more uncoupled haplogroups would
produce more heat (an adaptation to colder climates), be
more calorie restricted, and thus age better, but also be
more susceptible to certain mitochondrial diseases. This has
not been conﬁrmed directly, as comparison of uncoupling
in cell lines with identical genetic backgrounds repopulated
with mitochondria from haplogroups H and T did not show
any diﬀerences [114], but there are some results concerning
human lifespan under conditions of good and poor supply
which indicate that for instance persons with haplogroup H
livelongerthanpersonswithhaplogroupUunderconditions
when the food supply is limited [115]. Diﬀerences in
transcription between haplogroups have also been observed
[116], though a direct diﬀerence in uncoupling was not
analyzed. There are also some data indicating that mice with
moreuncoupledmitochondria livelongerthanmice without
the uncoupling [117]. However, there is a problem that few
oftheseassociation studieswouldfulﬁll thecriteria proposed
by Samuels et al. [118] as the analyzed groups were often too
small. Thus, the conclusion would be that there are interest-
ingsuggestionsofcorrelationsofmitochondrialhaplogroups
and aging, but the evidence is still too weak and may indeed
remain that way. On the other hand, there are new papers
indicating diﬀerences between some haplogroups for exam-
ple, between haplogroups H and UK in respect to among
others oxygen consumption and protein synthesis [119]a n d
persons with haplogroup H have been shown to have higher
mitochondrial oxidativedamage than thosewith haplogroup
J[ 120], and it is possible that this problem will be solved in
the future.
5.ReactiveOxygenSpeciesin
Carcinogenesisand Ageing
Multiple papers have indicated that oxidative stress is central
in the pathogenesis of a wide variety of diseases including
cancer and a special role in mitochondria-related ageing has
been attributed to reactive oxygen species (ROS) [1, 2, 121].
The mitochondrial respiratory chain is the major source of
ROS, which in excess obviously destroys mtDNA, in turn
contributing to the promotion of a vicious cycle of cancer
development and possibly aging. The constant generation of
ROS within the mitochondria and the increased oxidative
stress in cancer cells may cause further damage to the elec-
tron transport chain, and amplify respiratory malfunction
and cancer dependency on glycolysis. It is ROS production
that increases when electron transport is reduced or inhib-
ited, as in the case of low aerobic respiration rate resulting
from mtDNA mutations and aberrant OXPHOS protein
structure [122]. The main sources of mitochondrial ROS are
complexI and complexIIIsince mitochondrial generationof
ATP through oxidative phosphorylation involves formation
of O
−
2 and subsequently derived ROS such as hydrogen
peroxide and ·OH. This is the case of complex I ﬂavin
active site, complex I and complex III iron-sulfur centers
and ubisemiquinone transferring electrons to oxygen and
giving rise to superoxide anions. At the same time if the
respiratory chain is inhibited downstream of complex III (as
in the case of some mtDNA mutations), electrons coming
from succinate oxidation also increase superoxide anion
generation[123].Subsequently,oxidativestress developsand
ROS scavenging is overloaded [124, 125].
The scenario that emerges from ROS, mtDNA mutations
and cancer studies is rather complex [124, 125], since
diﬀerent mtDNA mutations do not result in the same proﬁle
intermsofROSproduction[23,40].Forexample,ithasbeen
proven that only mtDNA mutations that aﬀect the function
of complex I and III, but not COX mutations, are triggers
of ROS production [33] and that only speciﬁc mutations
in complex I genes with subsequent ROS overproduction
may promote tumor growth[17] and cancer metastases [15].
In contrast Zielonka and Kalyanaraman [126] recently have
proven that Ishikawa et al. [15] failed to show evidence for
formation of superoxide and hydrogen peroxide, presumed
to be generated from complex I deﬁciency associated with
mtDNA mutations in metastatic cells.
The involvement of ROS and mitochondria in cancer
appears to be generally accepted [127]. On the other hand,
the role of ROS in aging appears to be less well established,
in spite of the very long period in which it has been the
fundamental hypothesis for much of aging research. During
the last years a number of papers have suggested that
aging does not require ROS formation [128]a n dt h ef r e e
radical theory of aging has been increasingly under attack
and appears to be no longer the major theory explaining
this phenomenon [129, 130]. However, as is often true
for ﬁelds as complex as aging, the situation is not simple
and discussions as to the role of ROS will continue. This
paper deals essentially with mammals; however, recent work
on Drosophila melanogaster has shown that mitochondrial6 Journal of Aging Research
DNA controls longevity in females regardless of ROS pro-
duction, and moreover a number of predictions of the
mitochondrial free radical theory of aging were not veriﬁed
[131].
Interpretation of many results is quite complex. For
instance, Schriner et al. [132]h a v es h o w nt h a to v e r e x -
pression of catalase in mitochondria in mice extends their
lifespan. This could be construed as evidence that ROS
removal aﬀects longevity. The overexpression of this enzyme
not only alleviates aging symptoms in the heart in normal
mice [133] but also in the mutator mouse model [134].
Thus, the question is, if the mutator mouse ages without
ROS production, what does the catalase do in the heart
of these mice? Dubec et al. [135]o nt h eb a s i so fa
mouse model with a proofreading-deﬁcient mitochondrial
polymerase targeted only to the heart proposed that cell
death and cardiomyopathy are due to apoptosis caused by
rare mutations in mitochondrial DNA leading to the release
of an apoptosis-promoting peptide.
Where does this leave mitochondria? There are still
numerous data indicating their involvement in the aging
process—from model organisms [129, 136]t oh u m a n s
[1, 2]. Moreover, the exact mechanisms through which
mitochondrial function aﬀects aging is still unknown, what
does appear to be clear is that neither are ROS required for
aging nor does their production necessarily cause it.
6.Summaryand Perspectives
Preciseunderstandingofthemolecularmechanismswhereby
speciﬁc mtDNA polymorphisms predispose to cancer is
currently lacking. Although the mechanisms of generation
and functional impact of mtDNA polymorphisms are still
not clear, there is a high incidence and broad distribution
in human cancers making them a potential marker for
cancer detection, but the role of mtDNA polymorphisms
in the maintenance of the tumor cell phenotype or in
tumorigenesis remains to be elucidated [2, 3, 137, 138].
Although it is generally believed that polymorphisms may
have pathogenic potential, it remains to be established
whether they contribute to neoplastic transformation by
changingcellularenergycapacities,increasingmitochondrial
oxidativestress, or modulating apoptosis. The signiﬁcance of
each individual polymorphism for mitochondrial function
and tumorigenesis is unknown and only functional analysis
in relation to cell behavior, proliferation, and apoptosis
can determine the signiﬁcance of these polymorphisms
and their association with tumorigenesis. We believe that
polymorphisms in mtDNA, both in the D-loop and in
the coding region (including haplogroup-speciﬁc positions),
may causesubtlediﬀerencesintheencodedproteinstructure
and function [4, 12, 139]. Particular mtDNA genotypes
may predispose an individual to an earlier onset of degen-
erative cellular processes, such as the accumulation of
somatic mtDNA variation, decline in OXPHOS capacity or
faster cancer progression, as shown in transmitochondrial
cybrids [140] .T h em t D N Ah a p l o t y p em a ya l s oi n ﬂ u e n c e
its further mutagenesis, as has been shown for haplogroup
J that predisposes the mitochondrial genome to mutate
at locus 14484, possibly through near-neighbor eﬀects as
previously described to occur during mtDNA evolution
[141]. All these phenomena may aﬀect both cancer and
aging.
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